Application

Analytes: 5′-Nucleotidase (5′-NT/CD73), Liver-Type Arginase 1 (ARG1), Aspartate transaminase 1 (GOT1), α-Glutathione S-Transferase (GSTα), Sorbitol Dehydrogenase (SDH) Recommended Sample Type: Rat serum and plasma Recommended Sample Dilution: 25 µL per well of 1:25 diluted serum or plasma Assay Run Time: 2 hours at room temperature (20-25°C) Research Category: Toxicity

Components

Rat Liver Injury Standard, 1 vial, lyophilizedRat Liver Injury Quality Control 1, 1 vial, lyophilizedRat Liver Injury Quality Control 2, 1 vial, lyophilizedAssay Buffer, 1 bottle, 30 mLWash Buffer, 10X (0.05% Proclin), 2 bottles, 30 mL eaRat Liver Injury Detection Antibodies, 1 bottle, 3.2 mLStreptavidin-Phycoerythrin, 1 bottle, 3.2 mLMixing Bottle, 1 bottleSample Plate, 96 well format, 1 plate2 Foil Plate Sealers

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

General description

The MILLIPLEX^® Rat Liver Injury Bead Panel (RLI1MAG-92K) contains all the components necessary to simultaneous quantify the following 5 analytes in serum and plasma samples: Liver-Type Arginase 1 (ARG1)*, Aspartate transaminase 1 (GOT1), α-glutathione S-transferase (GSTα)*, Sorbitol Dehydrogenase (SDH)*, 5′-Nucleotidase/CD73 (5’;-NT). *ARG1, GSTα, and SDH are biomarkers listed in the Predictive Safety Testing Consortium (PSTC) project pipeline which have a strong translational role in drug safety testing. The MILLIPLEX^® portfolio provides a valuable research assay to investigate multiple biomarkers of liver injury in rat serum and plasma samples using the Luminex^® xMAP^® instrument platform. This kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 serum or plasma samples in duplicate. Drug toxicity is the leading cause of acute liver failure in the United States. Patients with liver damage generally display elevated amounts of specific liver proteins in serum; these proteins can serve as biomarkers of drug-related liver toxicity. Monitoring these biomarkers can greatly help clinicians avoid drug-induced liver failure. Performing laboratory tests to characterize the side effects of potential therapeutics is an essential part of drug development. The rat is a leading animal model for these pre-clinical toxicity studies. The search for sensitive, organ-specific toxicity biomarkers is complemented by the development of novel assays to measure these critical analytes. Liver-Type Arginase 1 (ARG1), α-glutathione S-transferase (GSTα), and Sorbitol Dehydrogenase (SDH) are biomarkers listed in the Predictive Safety Testing Consortium (PSTC) project pipeline which have a strong translational role in drug safety testing. Aspartate transaminase 1 (GOT1) and 5′-Nucleotidase / CD73 (5’;-NT) are traditional biomarkers recognized by both the Food and Drug Administration (FDA) and its European counterpart, the European Medicines Agency (EMA). Panel Type: Toxicity

Legal Information

xMAP is a registered trademark of Luminex Corp

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sensitivity: Please see kit protocol for individual assay sensitivities.

Please contact Technical Service for linearity of dilution.